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henzhf@imm.ac.cAbstract Methods of performing insulin clamps vary between laboratories. Here we present a
protocol of insulin clamping in conscious mice, with the signiﬁcant advantage of avoiding multiple
surgical catheterizations and non-physiologic metabolism during the induction of anesthesia. Using
this technique we also established a new method for measuring hepatic glucose production (HGP)
using a ﬂuorescent D-glucose analog, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglu-
cose (2-NBDG). To prove the reliability and feasibility of this method, whole-body insulin
sensitivity was compared between conscious normal ICR mice and diabetic KKAy mice using the
insulin clamp. Basal and clamp HGP was compared between normal C57 mice and diabetic db/db
mice by using the modiﬁed clamp with 2-NBDG as a tracer. The glucose infusion rate (GIR), an
index of insulin sensitivity, was signiﬁcantly lower in KKAy mice than normal ICR mice
(6.271.3 mg/kg/min vs. 31.372.9 mg/kg/min, Po0.001). The db/db mice also showed higher basal
hepatic glucose production (25.872.2 mg/kg/min vs. 16.772.5 mg/kg/min, Po0.05), higher clamp
HGP after insulin suppression (7.371.0 mg/kg/min vs. 0 mg/kg/min, Po0.001), and lower GIR
(71.672.8 mg/kg/min vs. 15.271.6 mg/kg/min, Po0.001) than that obtained with normal C57edica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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Shuainan Liu et al.404mice. In conclusion, this is the ﬁrst report of the application of 2-NBDG, rather than isotopic
tracers, for the determination of HGP in vivo.
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The hyperinsulinemic euglycemic clamp is widely considered
as the ‘‘gold standard’’ for assessing peripheral insulin sensi-
tivity and insulin action in vivo1. In recent years the insulin
clamp has been actively applied in transgenic and gene knock-
out animal models for understanding the action of target
genes on the etiology and pathogenesis of obesity and type 2
diabetes2–4. During clamping constant exogenous insulin
infusion is essential to raise the plasma insulin level to
eliminate endogenous insulin action, while an adjustable
glucose infusion is necessary to maintain euglycemia at
5.5–6.0 mM5. The glucose infusion rate (GIR) at the steady
state needed to maintain euglycemia is a reﬂection of insulin
action, as animals with enhanced insulin action require a much
greater GIR. Protocols for performing insulin clamps vary
between laboratories. In this paper, we present a new method
for the use of a hyperinsulinemic euglycemic clamp to evaluate
insulin sensitivity in conscious mice.
In type 2 diabetes the liver plays an important role in
maintaining both fasting and postprandial blood glucose
homeostasis by regulating hepatic glucose production
(HGP)6. The most frequently used method for assessing
hepatic glucose output and uptake is isotope dilution during
hyperinsulinemic euglycemic clamp. Isotopic tracers, including
2[14C] deoxyglucose and [3-3H] glucose are commonly used,
but have the disadvantage of generating radioactive waste and
biohazard7,8. Rather than measuring radioactivity, we have
established and optimized a ﬂuorescence spectroscopy method
to measure HGP using the ﬂuorescent substrate 2-NBDG
with the insulin clamp. The aim of the present study was to
develop a method to use 2-NBDG infusion to assess HGP. We
compare basal and clamp HGP between normal C57 mice and
diabetic db/db mice under the insulin clamp. We also provide a
method to calculate HGP using a modiﬁed version of Steele’s
non-steady state equation and present representative results
obtained using this modiﬁed insulin clamp.2. Materials and methods
2.1. Reagents and materials
D-Glucose was obtained from Beijing Chemical (Sinopharm
Chemical Reagent Company). Recombinant human insulin
injection was from Lilly France. Fetal bovine serum was
obtained from Atlanta Biologicals (Lawrenceville, GA). 2-
NBDG was from Invitrogen (Carlsbad, CA). Sodium pento-
barbital, sodium pyruvate and all other chemicals were
from Sigma. Micro-renathane implantation tubing (0.025 inch
O.D. 0.012 inch I.D.) was obtained from Braintree Scien-
tiﬁc, Inc. The Accu-Chek active blood glucose monitoring
meter and indicator papers were from Roche. Syringe infusionpump and Ismatec 4 channel low-speed and digital pump were
purchased from KD Scientiﬁc, Inc. and Cole Parmer Com-
pany. Fluorescence and chemiluminescence imaging system
(ChemiScope 2950) was purchased from CLiNX Science
Instruments Company. Corning (Lowell, MA) 96-well black
microplates with clear bottoms were used for detecting
ﬂuorescence intensity.
2.2. Animals
Normal ICR mice (male, 2 months of age, body weight about
35 g) and C57BL/6 mice (male, 4 months of age, body weight
about 35 g) were purchased from Vital River Laboratories and
diabetic KKAy (female, high-fat diet for 2 months, body
weight about 45 g) and db/db mice (male, high-fat diet for 1
months, body weight about 35 g) were from the Institute of
Laboratory Animal Science, CAMS & PUMC. All animals
were SPF inbred line and housed in an air-conditioned room
with a constant 12 h light/dark cycle at 2372 1C, and had free
access to water and chow. All animals were handled in
accordance with the Standards for Laboratory Animals
(GB14925-2001) and the Guideline on the Humane Treatment
of Laboratory Animals (MOST 2006a) established by the
People’s Republic of China.
2.3. Catheterization and postoperative recovery
In order to avoid the effects of anesthesia on heart rate, blood
ﬂow and hyperglycemia, we carried out a hyperinsulinemic
euglycemic clamp in conscious mice. Two groups of mice
(normal ICR mice and diabetic KKAy mice) were chosen for
assessing the whole-body insulin sensitivity in vivo.
Two groups of mice (n¼8/group) were catheterized and
allowed to recover for 5–7 days before the clamp experiments.
After anesthetization with sodium pentobarbital (50 mg/kg in
ICR mice and 70 mg/kg in KKAy mice), a single implantation
tubing was inserted into the right jugular vein for infusions.
The tubing was tunneled subcutaneously and exited at the
back of the neck, and attached via stainless steel connectors.
During the recovery period, the tubes were ﬂushed daily with
20 mL saline containing 50 IU/mL heparin sodium. Animals
were individually housed after surgery, and the body weights
were recorded daily.
2.4. Procedure for hyperinsulinemic euglycemic clamp
in conscious mice
We performed an insulin clamp in conscious normal ICR and
diabetic KKAy mice, a genetically obese rodent model of type
2 diabetes. Clamping was performed 5–7 days after catheter
implantations. After 15 h of fasting (5:30 PM–8:30 AM), two
groups of mice underwent 120-min clamp experiments. During
Figure 1 Protocol for hyperinsulinemic euglycemic clamps in conscious mice and the modiﬁed insulin clamp with 2-NBDG as a tracer.
The insulin clamp period consists of a constant insulin infusion and a variable glucose infusion. The GIR is adjusted accordingly to
maintain euglycemia (5.5 mM). The modiﬁed insulin clamp included an equilibration period with a primed infusion of 2-NBDG for
60 min prior to the clamp period. A constant infusion of 2-NBDG was maintained during the insulin clamp. Blood samples are collected
at the end of the equilibration period and during the steady state of the clamp for assessing basal and clamp hepatic glucose production.
Measuring HGP in mice using ﬂuorescent 2-NBDG 405the clamp the mouse was held in a restrainer while awake. The
setup and time lines for a typical experiment are shown in Fig. 1.
Mice were placed in an over-sized restrainer for about
30 min, and the tail tips were cut off for sampling during
clamp. Following the adaptation period, insulin clamping was
conducted and lasted for about 120 min. Human insulin was
infused at the rate of 20 mIU/kg/min through the indwelling
catheter. Blood glucose was monitored every 10 min. When
blood glucose levels fell to 6.0 mM, a glucose solution (10–
20%, w/v) was infused to maintain blood glucose levels at a
constant values at 5.570.5 mM. The glucose infusion rate
necessary to maintain euglycemia in the steady state reﬂects
the whole-body insulin sensitivity.2.5. Modiﬁed hyperinsulinemic euglycemic clamp
with 2-NBDG as a tracer
Two groups of mice (normal C57 and diabetic db/db mice,
n¼8/group) were fasted for 15 h (5:30 PM–8:30 AM) before
the clamp studies. Mice underwent a two-step hyperinsuline-
mic euglycemic clamp using 2-NBDG to measure the glucose
appearance and disappearance rate (Ra and Rd). Basal and
clamp HGP were calculated by using Steele’s equation (shown
in the next section). The setup and time lines for a typical
experiment are also shown in Fig. 1.
A priming dose of 2-NBDG (50 mM) was infused for 1 h
(the equilibration period). Blood glucose concentrations were
monitored using a glucose meter (Roche Diagnostics) from the
tail every 10 min, and then 15–20 mL blood samples were
collected for plasma 2-NBDG determinations. Following the
equilibration period, insulin clamping was conducted for
about 120 min. 2-NBDG (0.5 mmol/kg/min) was co-infused
with insulin (20 mIU/kg/min) through the vein catheter to
allow estimation of insulin-stimulated whole-body glucose
ﬂuxes. A glucose infusion (10–20%, w/v) was started when
the blood glucose levels fell to 6.0 mM. The glucose infusion
rate was adjusted every 10 min accordingly to maintain bloodglucose levels at 5.570.5 mM. Basal and clamp hepatic
glucose production was measured in the equilibration state
and during a minimal thirty-min steady state period at the end
of the clamp.
At the end of clamp, animals were euthanized with sodium
pentobarbital. The abdomen was quickly opened and tissues
(liver, epididymal fat, skeletal muscle) were exposed under a
ﬂuorescence imaging system. At completion of the clamp and
tissue imaging liver and soleus muscle were collected and
quickly frozen in liquid nitrogen for subsequent 2-NBDG
content determinations. A ﬂuorescence microplate reader was
used to measure the concentration of 2-NBDG in plasma and
tissue.2.6. Calculations
HGP were calculated at both the equilibration period of the
pre-clamp and during the last 30 min steady-state period of the
clamp. Tracer-determined rates were quantiﬁed by the Steele’s
equation9.
Basal hepatic glucose production was calculated as the ratio
of the pre-clamp 2-NBDG infusion rate to the speciﬁc
concentration of the plasma glucose (mean of the values in
the 30, 40 and 50 min of basal pre-clamp period). Steele’s non-
steady state equation is as follows (Basal HGP, mg/kg/min)10:
Basal HGP¼Ra¼ Total NBDGVp V Glucose½
DNBDG=Dt=Mean NBDG
where Total NBDG is the initial infusion rate of 2-NBDG
(mmol/kg/min), V is the 2-NBDG space or the volume of
distribution as 100 mL/kg body weight (mL/mg), and a
correction factor (Vp) of 0.6 was used. Glucose is the plasma
glucose concentration (mg/dL), DNBDG is the change in
plasma concentration of 2-NBDG during 10 min interval
(mmol/kg), and Dt is the time in min between the two samples.
Mean NBDG is the mean concentration in plasma during the
fasting period (mmol/mg).
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subtracting the glucose infusion rate from the total glucose
appearance rate during the ﬁnal 30 min of the clamp experiment.
Here, steady-state was achieved for plasma glucose concentration
and speciﬁc tracer concentration. In these conditions the rate of
glucose disappearance (Rd) equals the rate of glucose appearance
(Ra). Blood samples were collected during steady state condi-
tions. The hepatic glucose production during clamping was
determined by subtracting the average glucose infusion rate in
the last 30 min of clamp from the whole-body glucose uptake.
The hepatic glucose production in clamp was determined by
subtracting the GIR from total Rd. The equation is as follows
(Clamp HGP, mg/kg/min)11:
Rd¼RaV  DGlucose=Dt
Clamp HGP¼RdGIR
where DGlucose represent the change of mean concentration
of consecutive samples during steady state, which is equivalent
to zero. Both Ra and Rd were expressed per unit body mass
(mg/kg/min).
2.7. Pyruvate tolerance tests (PTT)
Fasting hyperglycemia in type 2 diabetes is linked to elevated
gluconeogenesis and HGP. Pyruvate tolerance tests were
generally used for assessing gluconeogenesis in liver. Admin-
istration of the gluconeogenic substrate sodium pyruvate
results in an increase of blood glucose levels.
Normal C57 and diabetic db/db mice were fasted overnight
and given an intraperitoneal injection of sodium pyruvate
(1.5 g/kg) dissolved in sterile saline. Plasma glucose levels were
determined by a glucose oxidase method in the tail tip
sampling at 0, 10, 20, 30, 60, 90, 120 and 180 min after the
injection. Area under the curve (AUC) of blood glucose in the
pyruvate tolerance test was calculated.
2.8. Statistics
Data were expressed as means7SEM. The comparison of
different groups was carried out using two-way ANOVA orFigure 2 Hyperinsulinemic euglycemic clamp in conscious diabetic
infusion rate (GIR) during the hyperinsulinemic euglycemic clamps in
Po0.001 vs. ICR group.t-test (two-tailed unpaired Student t-test) as appropriate.
Po0.05 was considered statistically signiﬁcant.3. Results
3.1. GIR is lower in KKAy mice than that in normal ICR mice,
indicative of whole-body insulin resistance
The results of insulin clamping in conscious mice are shown
schematically in Fig. 2. The overnight fasting blood glucose
level was signiﬁcantly higher in KKAy mice (8.570.4 mM)
relative to normal ICR mice (6.270.2 mM). Blood glucose
levels fell to 6.0 mM after insulin infusion (20 mIU/kg/min)
within 10 to 20 min in both groups. Glucose was infused
exogenously to maintain circulating blood glucose at the
target value of 5.5 mM. The steady-state blood glucose levels
were 5.570.5 mM in both groups (Fig. 2A). The glucose
infusion rate in steady state reﬂects whole-body insulin
sensitivity. GIR was decreased by 80% in KKAy mice
(6.271.3 mg/kg/min) compared with that of normal ICR mice
(31.372.9 mg/kg/min, Po0.001, Fig. 2B). The lower GIR is
indicative of impaired whole-body insulin sensitivity.3.2. Diabetic db/db mice exhibited elevated hepatic
gluconeogenesis compared to normal C57 mice in pyruvate
tolerance tests
Diabetic db/db mice exhibited higher overnight-fasted blood
glucose levels than normal C57 mice (17.773.5, 5.471.7 mM,
Po0.001, Fig. 3A), which might be due to increased gluco-
neogenesis. To assess this, pyruvate tolerance tests were
carried out. The peak of plasma glucose levels appeared at
20 min after sodium pyruvate injection in both groups. After
administration of sodium pyruvate, blood glucose levels in
db/db mice showed a greater increase than that in normal C57
mice. The AUC was also obviously increased in db/db mice
and was greater than that of normal C57 mice (61.876.3,
16.073.9 mM/h, Po0.001, Fig. 3B), indicating that db/db
mice had enhanced gluconeogenesis in the liver.KKAy and normal ICR mice. (A) Blood glucose. (B) Glucose
conscious mice. Values represent as means7SEM (n¼6–8/group).
Figure 3 Pyruvate tolerance tests in normal C57 and diabetic db/db mice fasted overnight. Blood glucose was monitored following
intraperitoneal administration of 1.5 g/kg sodium pyruvate. (A) Blood glucose. (B) The AUC; values represent as means7SEM (n¼6–8/
group). nnPo0.01, nnnPo0.001 vs. C57 group.
Figure 4 Glucose metabolism in normal C57 and diabetic db/db mice during hyperinsulinemic euglycemic clamps with 2-NBDG as a
tracer. (A) Blood glucose. (B) GIR. (C) The rate of basal hepatic glucose production. (D) The rate of clamp hepatic glucose production.
Values represent as means7SEM (n¼6–8/group). nPo0.05, nnPo0.01, nnnPo0.001 vs. C57 group.
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suppressed rates of hepatic glucose production as compared to
normal C57 mice
To further characterize the apparently enhanced gluconeogen-
esis in db/db mice, whole-body glucose disappearance and
production was analyzed by carrying out insulin clamps with
2-NBDG as a tracer.
The results of this modiﬁed insulin clamp are shown
schematically in Fig. 4. Under basal conditions prior to the
insulin clamp, basal hepatic glucose production in the type 2
diabetic db/db mice increased by 54.2% compare with that innormal C57 mice (25.872.2, 16.772.5 mg/kg/min, Po0.05,
Fig. 4C). The increase corresponded with the elevated over-
night-fasted plasma glucose concentration as shown in
Fig. 4A. Clamp hepatic glucose production may reﬂect
liver insulin sensitivity. Under normal circumstances endogen-
ous glucose production during clamping is low, and is
suppressed by a high exogenous insulin infusion. This was
validated in normal C57 mice, where the clamp HGP was close
to zero. In contrast, during the same high-concentration
insulin infusion clamp HGP in diabetic db/db mice was high
(7.371.0 mg/kg/min, Po0.001, Fig. 4D), indicating liver insulin
resistance.
Figure 5 Optical and ﬂuorescence imaging of glucose metabolism in tissues after hyperinsulinemic euglycemic clamp with 2-NBDG as a
tracer in normal C57 mice. (A) Visceral visible imaging. (B) Visceral ﬂuorescence imaging. (C) Hepatic visible imaging. (D) Hepatic
ﬂuorescence imaging.
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db/db mice compared to normal C57 mice (71.672.8 mg/kg/min
vs. 15.271.6 mg/kg/min, Po0.001, Fig. 4B), and served as
an index of impaired whole-body insulin sensitivity. To a great
extent the decreased GIR in db/dbmice could be attributed to the
enhanced hepatic glucose production during the clamp.3.4. Macroscopic ﬂuorescence imaging of 2-NBDG uptake
into highly metabolically active tissue after insulin clamp
To determine if glucose-sensitive uptake of 2-NBDG could be
visualized after the clamp and to identify tissues with the
greatest uptake, a whole animal ﬂuorescence imaging instru-
ment was used. The visible (Fig. 5A and C) and ﬂuorescent
(Fig. 5B and D) imaging of internal organs in normal C57
mice are shown.
As seen in Fig. 5B and Fig. 5D, the brighter ﬂuorescent
signal of 2-NBDG imaging indicated active metabolic areas.
There was a signiﬁcant ﬂuorescent signal of 2-NBDG accu-
mulation in the liver (as shown in red circle) and intestinal
tract (as shown in pink rectangle) after the modiﬁed insulin
clamp, but weak signaling in the muscle and other tissues.
To determine if the greater accumulation of 2-NBDG in liver
indicated higher glucose uptake and metabolism, the concentra-
tion of 2-NBDG in the liver was compared between normal C57
and db/db mice. Total 2-NBDG uptake in liver was increased by2.28-fold in normal C57 mice compared with diabetic db/db mice
(144.177.7 nmol/g/min vs. 63.274.4 nmol/g/min, Po0.01,
Table 1). This result indicates that the increased ﬂuorescent signal
in liver is due to increased 2-NBDG uptake during the clamp.
There were no signiﬁcant differences in total 2-NBDG uptake
into soleus muscle between two groups.4. Discussion
Hyperinsulinemic euglycemic clamps (insulin clamp) have
been widely applied in diabetes research and are considered
as a ‘‘gold standard’’ to evaluate the insulin sensitivity
in vivo11. In recent years insulin clamping could be used to
assess insulin action and glucose metabolism both in anesthe-
tized and conscious animal models, including mice, rats, dogs
and cats12–15. However, assessment of glucose metabolism in
anesthetized mice yields biochemical data that are not phy-
siological. As a result, insulin clamping is preferred in
conscious mice for minimizing the stress and intervention of
anaesthesia.
Although the general protocol for an insulin clamp in
conscious mice is well-known, parameters such as the site of
blood sampling and insulin infusion rates vary from one
laboratory to another. In our laboratory only one catheter is
inserted into the right jugular vein for infusions before the
clamp experiment, and blood samples were obtained from the
Table 1 2-NBDG uptake in liver and soleus muscle in
normal C57 mice and db/db mice during insulin clamping.
Animal Liver 2-NBDG
uptake
(nmol/g/min)
Soleus 2-NBDG
uptake
(nmol/g/min)
C57 mice 144.177.7 44.674.8
db/db mice 63.274.4a 38.672.1
Values represent as means7SEM (n¼6–8/group)
aPo0.01 vs. C57 group.
Measuring HGP in mice using ﬂuorescent 2-NBDG 409cut tail method rather than the artery, with the need to
restrain the mouse on a warming pad. This technique provides
a signiﬁcant advantage over the more common methods by
avoiding multiple operations on the jugular vein and artery16.
Because the sample volume needed is small during the
clamp—typically 5–10 mL or less, the stress from tail cutting
is very small. Initial priming doses of insulin as high as
300 mIU/kg reported in other insulin clamp experiments are
unnecessary in our clamp17. If an insulin priming dose is
administered, the delayed response to the insulin could extend
the later glycemia adjustment period for 30 to 60 min. Thus,
we chose a high infusion rate of 20 mIU/kg/min of insulin
from the initial phase of the clamp, and the blood glucose was
decreased to 6.0 mM within 10 to 20 min in both the insulin
resistant KKAy mice and diabetic db/db mice.
As described above, isotopic tracer infusions are usually
used to assess glucose ﬂux and sites of insulin action. The most
commonly used isotopes are [3-3H] glucose for the assessment
of rates of HGP and Rd, and 2[14C] deoxyglucose for the
assessment of tissue-speciﬁc glucose uptake at the end of
clamp18. But isotope tracers have limitations such as poor
spatiotemporal resolution. To develop a practical and less
biohazardous approach, we tested 2-NBDG, a ﬂuorescent
glucose analog that has been used to monitor glucose utiliza-
tion in live cells19–21. Although sensitive to its environment,
NBD ﬂuorescence typically displays excitation/emission max-
ima of 465/540 nm and can be visualized using optical ﬁlters
designed for ﬂuorescein22,23. Measurement of HGP in clamps
by ﬂuorescence has not previously been described. When
2-NBDG was infused in conjunction with an insulin clamp,
its levels could be measured using a ﬂuorescence microplate
reader, allowing measurement of the ability of insulin to
suppress, and to stimulate the endogenous glucose appearance
(Ra) and glucose disappearance (Rd). The rate of Ra is a
marker of hepatic glucose production. In the clamp, the
2-NBDG is infused to an animal fasted overnight to evaluate
basal HGP. In the fasting state HGP is easily calculated as a
non-steady-state condition. Baseline blood samples (30 mL) for
2-NBDG analysis are taken every 10 min during the basal
period (t¼60 to 0 min). During insulin or glucose infusion
samples of clamp plasma 2-NBDG are taken at t¼90, 100,
110 and 120 min. Under these conditions we have obtained the
results shown in Fig. 4. Along with the decreased glucose
disposal rate and glucose infusion rate, liver insulin sensitivity
was signiﬁcantly impaired in the diabetic db/db mice, as
evidenced by attenuated suppression of hepatic glucose pro-
duction during the clamp (Fig. 4B). These data were consistent
with that obtained using the PTT, which proved the reliability
and feasibility of this modiﬁed clamp technique with 2-NBDG
as a tracer.
As shown in Fig. 5, there was a marked and signiﬁcant
increase in the 2-NBDG signal in the liver as compared to
other tissues after the insulin clamp, suggesting that 2-NBDG
uptake accurately reﬂects the utilization of glucose in liver.
These data corroborate the whole animal imaging data and
support 2-NBDG as a speciﬁc marker of liver glucose uptake
and metabolism. We tried to determine the concentration of
2-NBDG in skeletal muscle, which may represent glucose
disposal. There was no signiﬁcant difference between the
normal and diabetic mice models (as shown in Table 1).
Although inconsistent with the impaired insulin sensitivity
ﬁnding, diabetic mice did not show lower 2-NBDG levels inthe soleus muscle, which indicates that in our protocol the
2-NBDG uptake in muscle did not accurately represent the
glucose uptake. These results suggest that this technique may
need to be coupled with a 2[14C] deoxyglucose technique for
the assessment of tissue-speciﬁc glucose uptake in this tissue
during insulin clamp24,25.5. Conclusions
The hyperinsulinemic euglycemic clamp is essential to the
study of glucose metabolism and insulin action in vivo. For
investigators using the clamp technique in a new animal model
or in animals after drug intervention, it is crucial that tests are
conducted correctly to guide subsequent mechanistic studies.
We have established an insulin clamp with a minimal surgery
and with adequate parameters for evaluating insulin sensitivity
in conscious mice. We also present a modiﬁed insulin clamp
method with 2-NBDG as a ﬂuorescence tracer. These techni-
ques can be used to assess not only whole-body insulin
sensitivity, but also hepatic glucose production. The applica-
tion of 2-NBDG can also provide ﬂuorescence imaging
modalities, highlighting its potential in detection of hepatic
glucose metabolism.Acknowledgments
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